Amendments to the Claims

The following Listing of Claims will replace all prior versions and listings of claims in the above-referenced application.

Listing of Claims:

Claims 1-15. (Canceled)

16. (New) A pharmaceutical composition for delivering a therapeutically effective amount of an epothilone macrolide to a mammal, the pharmaceutical composition comprising:

an amount of an epothilone macrolide; and

a pharmaceutically acceptable carrier selected from the group consisting of glycols, oils, and alcohols,

wherein the amount of the epothilone macrolide in the carrier is sufficient for the composition to deliver to the mammal between about 0.001 mg and about 0.6 mg of epothilone macrolide per kg body weight.

17. (New) The pharmaceutical composition of claim 16, wherein the therapeutically effective amount is an amount sufficient to deliver about 0.01 mg to about 0.6 mg of epothilone macrolide per kg body weight.

18. (New) The composition of claim 16, wherein the composition is formulated for parenteral delivery.

19. (New) The composition of claim 16, wherein the composition is formulated for oral delivery.

20. (New) The composition of claim 16, wherein the composition comprises an emulsion.

21. (New) The composition of claim 16, wherein the composition comprises an aqueous suspension.

22. (New) A method of treating cancer in a subject comprising:

administering to the subject in need thereof an average daily dose of an epothilone macrolide; and

a pharmaceutically acceptable carrier selected from the group consisting of glycols, oils, and alcohols,

wherein the amount of the epothilone macrolide in the carrier is sufficient for the composition to deliver to the subject between about 0.001 mg and about 0.6 mg of epothilone macrolide per kilogram of the subject's body weight.

23. (New) The method of claim 22, wherein the average daily dose is within the range of about 0.01 mg to about 0.6 mg of epothilone macrolide per kg body weight.

24. (New) The method of claim 22, wherein the step of administering comprises administering individual doses not more frequently than once daily.

25. (New) The method of claim 22, wherein the step of administering comprises interrupting individual dose administrations with at least one day of rest.

26. (New) The method of claim 22, wherein the step of administering comprises interrupting individual dose administrations with at least three days of rest.

27. (New) The method of claim 22, wherein the step of administering comprises administering over a period of at least about 6 days.

28. (New) The method of claim 22, wherein the step of administering comprises administering to an animal that has a multidrug resistant tumor.

29. (New) The method of claim 22, wherein the step of administering according to a schedule sufficient to achieve at least about 16% tumor inhibition.